Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years

Conclusion: The uptake and use of the oral DMTs increased substantially over the first 2 to 5 years after their introduction. These recent changes highlight the importance of monitoring the risks and benefits in the real world.